Navigation Links
WellWorld Science(R) Announces U.S. Launch of Livea(R),a Safe and Natural Appetite Control Supplement
Date:1/27/2010

LAS VEGAS, Jan. 27 /PRNewswire/ -- After more than 30 years of research and an extensive open-label weight loss study, WellWorld Science® announces the official U.S. launch of Livea®, a doctor-developed, non-prescription, patent-pending appetite-control supplement that is unlike any other dietary supplement on the market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100127/NY44298 )

New research in neuropeptides has shown that certain people may have a medical issue causing an internal disconnect, which can lead to long-term health consequences that include obesity, heart disease and diabetes.  For a person living with this signaling defect, the normal digestive process that alerts the brain to stop eating may not work, leading these individuals to overeat until they have a feeling of being stuffed; and even then they may still feel the urge to eat.  Livea® mimics the body's natural signaling process making the body feel full, leading to weight loss.  And because the proprietary blend of ingredients is all-natural, it can be safely consumed for an extended period, unlike other products that can have long-term, adverse side effects after short-term use.

According to Joseph Fayad, M.D., FACP, FACG, a nationally-recognized gastroenterologist and leading expert at the forefront of neuropeptide research, "Based on an independent, open-label weight loss study, Livea® demonstrated that it safely and effectively helped patients consume fewer calories than those who did not take the supplement."  In fact, among the participants in this study, both men and women reported weight loss ranging between 18 and 59 pounds.(1)  Fayad continues, "These peptides, which Livea® activates, are being studied in their role in treating fatty liver disease, improving various organ functions and treating diverse autoimmune disorders, including Type II Diabetes and Multiple Sclerosis."

Weight loss study participants included Kai Hibbard, runner-up on the third season of The Biggest Loser®.  Kai has lost and kept off 67 pounds since starting the Livea® program as part of the open-label study in January 2009. According to Hibbard, now an AAFA-certified aerobics instructor, the hardest part about keeping the weight off after the show was combating the cravings following an "extreme diet."

"I would begin my day with the intention of eating healthy, but by the middle of the night when I was awake to feed my newborn, I was gorging on cookies," says Hibbard.  "The cravings had control over me, and I was feeling like a failure for not being able to maintain all the good habits I'd learned after being a part of the show."

Following her success, Kai joined the Livea® team as their spokesperson and is featured in their marketing program, including a series of two-minute commercial spots on cable, select regional broadcast markets and its website.  The spots also profile other participants who experienced amazing results as part of the study.

The positive results of Livea® and its Lifestyle Program go well beyond the weight loss benefits.  With current research showing a link between neuropeptide deficiency and many common health concerns, Livea® is not just leading the way in weight management but is breaking new ground for what may become the science of the future.

Livea®, manufactured in the USA, is now available online at www.Livea.com and in select doctor's offices and clinic outlets. To learn more about Livea®, visit www.Livea.com.

ABOUT WELLWORLD SCIENCE®

WellWorld Science® develops and distributes a series of non-pharmaceutical/nutraceutical products specifically targeted to improve consumers' general health, wellness, and well being. The Company's products, in general, target the ever-expanding global epidemic of the overweight condition and obesity. The Company's cornerstone product, Livea®, is a patent-pending appetite control product that has mass appeal to the millions of adults in the United States considered overweight or obese by virtue of solving the issue of portion control and the feeling of satiety. Livea® was developed and is distributed by WellWorld Science®. Livea® and WellWorld Science® are registered trademarks of WellWorld Science®. ©2009 WellWorld Science®. All rights reserved. FDA WARNING: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

(1) http://www.livea.com/docs/study.pdf

SOURCE WellWorld Science(R)

RELATED LINKS
http://www.livea.com

'/>"/>

SOURCE WellWorld Science(R)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)...  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" ... of its issued and outstanding shares of common stock ... 11, 2016. The Company,s common stock will trade on ... temporary ticker symbol "RCHAD". After 20 trading days, the ... (RCHA).  --> --> ...
(Date:2/10/2016)... , Feb. 10, 2016  The Baylor ... received an in-kind gift from ... VeinViewer® Vision vein finder for the nursing ... students as they learn how to start ... with traditional technique. ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s ... together more than 200 of the country’s top healthcare executives to share insights ... true benefit of the Forum is the provider-centric perspective, experience, expertise and strategy ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau ... Center. , As the longest running and largest worker's compensation event in ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions ... Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social Media: ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans ... start of Medicare Part D a decade ago, according to The Senior Citizens ... adults on how they are coping with rapidly rising costs. “The implications are ...
Breaking Medicine News(10 mins):